R11 modified tumor cell membrane nanovesicle-camouflaged nanoparticles with enhanced targeting and mucus-penetrating efficiency for intravesical chemotherapy for bladder cancer
Bin Zheng,Zhenghong Liu,Heng Wang,Li Sun,Wing-Fu Lai,Haibao Zhang,Jinxue Wang,Yang Liu,Xiaowen Qin,Xiaolong Qi,Shuai Wang,Youqing Shen,Pu Zhang,Dahong Zhang
DOI: https://doi.org/10.1016/j.jconrel.2022.09.055
IF: 11.467
2022-11-01
Journal of Controlled Release
Abstract:Intravesical chemotherapy is generally used in the clinic for treating bladder cancer (BCa), but its efficacy is limited due to the permeation barrier and side effects caused by the off-targeting of normal urothelial cells. In this study, BCa cell-derived membrane nanovesicles were used as drug carriers, and their homologous tumor-targeting capacity was utilized. A BCa-targeting hendeca-arginine peptide was functionalized onto the nanovesicles to impart a mucus-penetrating ability and thus overcome the permeation barrier. The tumor-targeting and mucus-penetrating nanovesicles were stable in urine, were highly permeable to the glycosaminoglycan layer, and specifically targeted BCa. The vesicles were internalized through caveolin-mediated endocytosis, were transported to nonlysosome-localized intracellular regions, and efficiently infiltrated bladder tumor spheroids. In in vivo intravesical chemotherapy, the nanovesicles achieved chemo-resection in murine orthotopic BCa models. This BCa-targeting and mucus-penetrating drug delivery system may be promising for the intravesical chemotherapy of BCa.
pharmacology & pharmacy,chemistry, multidisciplinary